摘要
目的:通过观察华蟾素酯蟾毒配基类有效组分在体内对免疫相关细胞因子的影响,分析药物对机体免疫系统的调节作用,为阐明其免疫作用机制提供药理学和药效学依据。方法:体外培养人胰腺癌肿瘤细胞As PC-1,建立As PC-1胰腺癌荷瘤裸鼠动物模型,待给药结束后,通过流式细胞术的高通量多因子检测技术对小鼠血清进行粒细胞巨噬细胞集落刺激生物因子(GM-CSF),肿瘤坏死因子-α(TNF-α),干扰素-γ(IFN-γ),白细胞介素-1α(IL^(-1)α),白细胞介素-2(IL-2),白细胞介素-4(IL-4),白细胞介素-5(IL-5),白细胞介素-6(IL-6),白细胞介素-10(IL^(-1)0)检测,并用蛋白质免疫印迹法(Western blot)检测组织中相应细胞因子的蛋白含量,评价其体内免疫效果。结果:酯蟾毒配基类有效组分体内作用As PC-1胰腺癌荷瘤裸鼠免疫效果观察发现,与吉西他滨和华蟾素注射液比较,配基类组分能更多的增强细胞因子的表达。同时低剂量组对脾脏有一定的保护作用,高剂量组对脾脏的作用与华蟾素注射液和化疗药物吉西他滨相当。结论:华蟾素酯蟾毒配基类有效组分在体内能引起多种免疫相关细胞因子的分泌,增强机体的免疫功能,但具体的免疫作用机制还有待进一步研究。
Objective： To observe and the influence of bufadienolides on the immune-related cytokines in vivo, analyze the effect of drug on immune system regulation, and provide the pharmacological and pharmacodynamics evidences to clarify its immune mechanism. Method： After the As PC-1 pancreatic cancer tumor cells were cultured in vitro,the animal models of As PC-1 pancreatic cancer were established in nude mice. After administration for a certain time,flow cytometry with high throughput and multi-factor detection technology was used to detect the cytokines of granulocyte-macrophage colony stimulating factor（ GM-CSF）,tumor necrosis factor-α（ TNF-α）,interferon-γ（ IFN-γ）,interleukin^（-1）α（ IL^（-1）α）,interleukin-2（ IL-2）,interleukin-4（ IL-4）,interleukin-5（ IL-5）,interleukin-6（ IL-6） and interleukin^（-1）0（ IL^（-1）0） in mice serum. Western blot assay was used to detect the protein content of corresponding cytokines in tissues,and its immune effect in vivo was evaluated. Result： In the observation of the drug＇s immune effect on pancreatic cancer tumor-bearing nude mice in vivo,as compared with gemictabine and cinobufotalin injection, bufadienolides can enhance more cytokine expression. The low dosage group had protective effect on spleen while high dosage group achieved the same effect on spleen as gemictabine and cinobufotalin injection. Conclusion： Bufadienolides can lead to secretion of various immune-related cytokines,enhance the body＇s immune function,but the specific mechanism of immune function still needs further research.
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2016年第21期87-92,共6页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家"重大新药创制"科技重大专项(2013ZX09102025)
